Respiratory, Inflammation and Autoimmunity, Biotech IMED Unit, AstraZeneca, Gothenburg, Sweden.
Respiratory, Inflammation and Autoimmunity, Biotech IMED Unit, AstraZeneca, Gothenburg, Sweden.
J Allergy Clin Immunol. 2019 Jul;144(1):61-69.e7. doi: 10.1016/j.jaci.2019.01.027. Epub 2019 Feb 4.
Group 2 innate lymphoid cells (ILC2s) are effective producers of IL-5 and IL-13 during allergic inflammation and bridge the innate and adaptive immune responses. ILC2 numbers are increased in asthmatic patients compared with healthy control subjects. Thus far, human data describing their phenotype during acute allergic inflammation in the lung are incomplete.
This study aims to characterize and compare blood- and lung-derived ILC2s before and after segmental allergen challenge in patients with mild-to-moderate asthma with high blood eosinophil counts (≥300 cells/μL).
ILC2s were isolated from blood and bronchoalveolar lavage (BAL) fluid before and after segmental allergen challenge. Cells were sorted by means of flow cytometry, cultured and analyzed for cytokine release or migration, and sequenced for RNA expression.
ILC2s were nearly absent in the alveolar space under baseline conditions, but numbers increased significantly after allergen challenge (P < .05), whereas at the same time, ILC2 numbers in blood were reduced (P < .05). Prostaglandin D and CXCL12 levels in BAL fluid correlated with decreased ILC2 numbers in blood (P = .004, respective P = .024). After allergen challenge, several genes promoting type 2 inflammation were expressed at greater levels in BAL fluid compared with blood ILC2s, whereas blood ILC2s remain unactivated.
ILC2s accumulate at the site of allergic inflammation and are recruited from the blood. Their transcriptional and functional activation pattern promotes type 2 inflammation.
在过敏炎症期间,2 型固有淋巴细胞(ILC2)是 IL-5 和 IL-13 的有效产生者,并在先天和适应性免疫反应之间架起桥梁。与健康对照受试者相比,哮喘患者的 ILC2 数量增加。到目前为止,描述其在肺部急性过敏炎症期间表型的人类数据尚不完全。
本研究旨在表征和比较高嗜酸性粒细胞计数(≥300 个/μL)的轻度至中度哮喘患者在接受节段性变应原挑战前后血液和肺来源的 ILC2。
在接受节段性变应原挑战之前和之后,从血液和支气管肺泡灌洗液(BAL)中分离 ILC2。通过流式细胞术对细胞进行分选,进行培养和分析细胞因子释放或迁移,并进行 RNA 表达测序。
在基线条件下,ILC2 在肺泡空间中几乎不存在,但在变应原挑战后数量显著增加(P <.05),而同时血液中的 ILC2 数量减少(P <.05)。BAL 液中的前列腺素 D 和 CXCL12 水平与血液中 ILC2 数量减少相关(P =.004,分别为 P =.024)。在变应原挑战后,与血液 ILC2 相比,BAL 液中促进 2 型炎症的几个基因表达水平更高,而血液 ILC2 仍未被激活。
ILC2 在过敏炎症部位聚集,并从血液中招募。它们的转录和功能激活模式促进了 2 型炎症。